Agoracom Blog Home

Archive for the ‘Medical Marijuana Stocks’ Category

« Older Entries
Newer Entries »

$APPB Applied BioSciences Expands TherPet Line with Equine Care Line

Posted by AGORACOM at 10:55 AM on Wednesday, May 9th, 2018

  • TherPet has entered the equine health space
  • Launched hemp-derived cannabidiol (“CBD”) formulated specifically for a horse’s health and wellness
  • Horses also have an endocannabinoid system comprised of cannabinoid receptors that help regulate a wide variety of bodily functions ranging from pain relief to mood.

 

LOS ANGELES, CA / May 9, 2018 / Applied BioSciences Corp. (OTCQB: APPB), a diversified cannabinoid therapeutics company focused on the medical, bioceutical and pet health industries, today announced that the Company’s wholly-owned animal health subsidiary TherPet has entered the equine health space with the launch of a new full-spectrum hemp-derived cannabidiol (“CBD”) supplement formulated specifically for a horse’s health and wellness.

TherPet’s Equine Care CBD line is a natural supplement designed to play a key role in keeping horses, healthy, looking good and performing their best. Our Equine Care CBD products support healthy skin, joints and immune system as well as to ease the discomfort of fatigued muscles, stiff joints and arthritis pain.

Like humans, horses also have an endocannabinoid system comprised of cannabinoid receptors that help regulate a wide variety of bodily functions ranging from pain relief to mood.

“Regularly supplementing a horse’s endocannabinoid system with full-spectrum CBD enables horses to better control inflammatory responses naturally,” noted JJ Southard, Vice President of Products at Applied BioSciences Corp. “Despite millions of spectators tuning in to watch twenty of the fastest thoroughbred horses compete in the Kentucky Derby this past weekend, very few of them realize or consider the race-induced inflammation and injuries that take place during such an event.”

David Horohov, Ph.D., William Robert Mills Chair at the University of Kentucky’s Gluck Equine Research Center, believes that horses as a breed are not necessarily becoming more fragile, but rather more susceptible to injury due to breeding strategies, training methods, and increased drug use. The Company hopes to reverse this trend by making Therpet’s new treatment options available immediately for veterinarians, trainers, and equestrians.

Therpet’s Equine Care tincture is available in a 4800 mg concentration which is packaged in a 4 fl. Oz. (120ml) bottle. The tincture is a naturally formulated Apple flavor, made with lab tested, CO2 extracted, pure full-spectrum CBD oil sourced from pesticide-free, Colorado grown hemp and specially formulated to be the highest bioavailability CBD products in the marketplace.

TherPet products are USDA NOP certified organic, non-GMO, vegan, paleo, gluten-free, sugar-free and THC-free. The products are formulated with organic 99%+ pure cannabidiol along with our proprietary blend of certified organic botanical, herbal and essential oils to further optimize bioavailability.

About Applied BioSciences Corp.

Applied BioSciences Corp. (www.appliedbiocorp.com), is a diversified company focused on multiple areas of the medical, bioceutical and pet health industry. As a leading company in the CBD and Pet health space, the company is currently shipping to the majority of US states as well as to 5 International countries. The company is focused on select investment, consumer brands, and partnership opportunities in the recreational, health and wellness, nutraceutical, and media industries.

The company has several strategic partnerships and investments currently in place and is actively pursuing additional partnerships and strategic growth opportunities.

Contact

Email: [email protected] or [email protected]

To be added to the Applied BioSciences email distribution list, please email [email protected] with APPB in the subject line.

Official Website: www.appliedbiocorp.com

Brands:

www.remedishop.com
www.therpet.com

Follow us:

Facebook @remedicbd & @therpetcbd
Instagram @remedicbd & @therpet
Twitter @remedishop & @therpet

Tags: , ,
Posted in All Recent Posts, Featured, Medical Marijuana Stocks, Small and Micro-Cap Space | Comments Off on $APPB Applied BioSciences Expands TherPet Line with Equine Care Line

Marijuana Company of America’s $MCOA hempSMART(TM) Brand Engages Kim Castle and Verve Integrative to Manage Television Ad Campaign for Its CBD Product Line $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 9:12 AM on Friday, May 4th, 2018

15233 mcoa

  • Wholly owned subsidiary, H Smart, Inc. has engaged Kim Castle of Verve Integrative to create a market strategy and manage a direct response television ad campaign to promote its hempSMART™ product line.
  • Budget for the DRTV program is approximately $100,000.

Escondido, California–(May 4, 2018) – MARIJUANA COMPANY OF AMERICA INC. (OTC Pink: MCOA) (“MCOA” or the “Company“), an innovative hemp and cannabis corporation, is pleased to announce that its wholly owned subsidiary, H Smart, Inc. has engaged Kim Castle of Verve Integrative to create a market strategy and manage a direct response television (DRTV) ad campaign to promote its hempSMART™ product line.

The Company anticipates that its recently announced EPCO direct sales marketing campaign, in conjunction with the upcoming DRTV marketing campaign and the Company’s ongoing network marketing campaign should result in an improvement in hempSMART™ product sales in Q3 and Q4 2018. The budget for the DRTV program is approximately $100,000.

hempSMART™ is working with Ms. Castle of Verve Integrative and their experienced marketing team to develop a market strategy and a television commercial for the hempSMART™ Pet Drops that will air on cable networks in select regions nationally this summer. The hempSMART™ commercial spot will have featured placement on the official eCommerce site of a well-known DRTV company and will be broadly promoted on integrated social media outlets, benefiting from well-established consumer engagement strategies.

Ms. Castle is leading a team that has more than 25 years of experience in many variations of media strategy, development and production, working for Disney, GM, ABC, Paramount, GreyGroup and McCann, to mention just a few. They specialize in multipoint story experiences designed to educate, entertain and endorse while mirroring the human mind’s process of solving a problem, thereby supporting consumers in making emotional and logical product conclusions. Ms. Castle’s experience both in front of and behind the camera provides an invaluable edge to the hempSMART™ marketing campaign.

In addition, Ms. Castle has personally been an advocate of CBD as an alternative to traditional products currently on the market. “We are very pleased to partner with hempSMART™ on their journey to bring such thoughtful and well-developed products to the people who need natural relief and enhanced health solutions. I wish hempSMART™ Pet Drops were available to support my cherished dog when we were going through a health challenge together,” said Castle.

Donald Steinberg, CEO of MCOA, stated “Kim’s experience gives us an excellent opportunity to greatly expand the marketing strategy for the hempSMART™ brand and product line. We are honored that the hempSMART™ product line will be managed by her and the Verve Integrative team. We look forward to the new television commercial airing this summer.”

About Marijuana Company of America, Inc.

MCOA is a corporation which participates in: (1) product research and development of legal hemp-based consumer products under the brand name “hempSMART™”, that targets general health and well-being; (2) an affiliate marketing program to promote and sell its legal hemp-based consumer products containing CBD; (3) leasing of real property to separate business entities engaged in the growth and sale of cannabis in those states and jurisdictions where cannabis has been legalized and properly regulated for medicinal and recreations use; and, (4) the expansion of its business into ancillary areas of the legalized cannabis and hemp industry, as the legalized markets and opportunities in this segment mature and develop.

About Our hempSMART Products Containing CBD

The United States Food and Drug Administration (FDA) has not recognized CBD as a safe and effective drug for any indication, and disclaims CBD as a dietary supplement. Our products containing CBD derived from industrial hemp are not marketed or sold based upon claims that their use is safe and effective treatment for any medical condition.

Forward Looking Statements

This news release contains “forward-looking statements” which are not purely historical and may include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities and words such as “anticipate”, “seek”, intend”, “believe”, “estimate”, “expect”, “project”, “plan”, or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects, the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based products. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-12G, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission. For more information, please visit www.sec.gov.

For more information, please visit the Company’s websites at:

MarijuanaCompanyofAmerica.com
hempSMART.com
NetworkNewsWires/MCOA

Corporate Communications Contact:
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
[email protected]

Tags: , ,
Posted in All Recent Posts, Marijuana Company of America, Medical Marijuana Stocks | Comments Off on Marijuana Company of America’s $MCOA hempSMART(TM) Brand Engages Kim Castle and Verve Integrative to Manage Television Ad Campaign for Its CBD Product Line $AERO $CBDS $CGRW $APH.ca $GBLX

Namaste $N.ca Acquires #Findify, a Leading A.I. and Machine Learning Company, to Increase Conversion Rates, Average Order Value, Retention and Referrals $ACB.ca $HIP.ca $WEED.ca $CMED.ca

Posted by AGORACOM-JC at 11:06 AM on Wednesday, May 2nd, 2018

Nlogo

  • Company executed a definitive agreement to acquire all of the issued and outstanding shares of Findify AB
  • purchase price of US $12,000,000 in a combination of cash and common shares of the Company
  • Findify is a global leader in A.I. powered e-commerce personalization, delivering solutions such as personalized search, recommendations, and advanced data analytics

VANCOUVER, British Columbia, May 02, 2018 – Namaste Technologies Inc. (“Namaste” or the “Company”) (TSX-V:N) (FRA:M5BQ) (OTCMKTS:NXTTF) is pleased to announce that on May 1, 2018 the Company executed a definitive agreement to acquire (the “Acquisition”) all of the issued and outstanding shares of Findify AB (a Swedish corporation, “Findify”), for a purchase price of US $12,000,000 in a combination of cash and common shares of the Company. Findify is a global leader in A.I. powered e-commerce personalization, delivering solutions such as personalized search, recommendations, and advanced data analytics. Among its customers are Nine West, PLV Shoes, and Rocketdog.

Management expects the integration of Findify’s proprietary technology to increase monetization and propel revenue growth in both cannabis and hardware sales. In addition to anticipated growth in Namaste’s core business, the Company will allocate resources to expand on Findify’s existing platform and expects this to result in increased EBITDA by the end of 2019. Namaste also anticipates accelerating patient growth through its wholly owned subsidiary and Canada’s first fully-compliant online patient portal, NamasteMD Inc. (“NamasteMD” or “NamasteMD.com”). By implementing Findify’s technology in applications of patient acquisition, conversion rates, order value and customer retention, the Company expects to reach 50,000 medical cannabis patients by the end of 2018 and up to 100,000 by the end of 2019.

Findify’s platform which is used by leading e-commerce websites, including Namaste, uses proprietary real-time machine learning algorithms to build unique user profiles, and deliver a personalized experience for each user. The platform continuously learns from user behavior to automatically improve search results, recommendations, and product landing pages, displaying the most relevant products at any given time. It identifies product trends and, in combination with an analysis of unique customer behavior, ranks products in a way to optimize revenue, conversion rates and average order value. Based on the Bank of Canada’s exchange rate on May 1, 2018, Findify’s annual 2017 revenue was $503,170 and its first quarter 2018 revenue was $198,211.

Key terms of the Acquisition:

  • Namaste will acquire all issued and outstanding shares of Findify in exchange for:
    • US $2,000,000 in cash to be paid upon the closing date of the transaction.
    • US $10,000,000 to be paid in common shares of Namaste at a mutually agreed price of C$1.80 per common share.

Key designated employees of Findify will be remaining with the company after the completion of the acquisition.

The acquisition of Findify brings an incredible amount of value to the Company in applications related to the online retail of medical cannabis. Namaste recognizes this as a unique opportunity to offer medical cannabis patients an even more personalized experience. The acquisition of Findify will reinforce Namaste’s goal of becoming the global leader in cannabis technology solutions by further expanding its innovative e-commerce platform and enhancing the user experience for cannabis patients globally.

In addition, the acquisition of Findify creates a new revenue stream for the Company in the field of artificial intelligence and data analytics. Namaste will continue to operate and expand on Findify’s existing platform and client portfolio.  Namaste anticipates rapid expansion of its technology licensing business.

Management Commentary

Meni Morim, Founder and CEO of Findify comments: “The Findify team is very excited to join the Namaste family, and take part in revolutionizing the online cannabis domain. The team brings years of experience, having built a unique machine learning platform that leverages user behavior, to deliver a personalized e-commerce experience across touchpoints, with a focus on search & discovery. We believe that Namaste’s strong positioning in the market will enable us to take advantage of this technology in the best possible way, and deliver immediate value to customers and shareholders – by buildings the world’s first fully integrated A.I. platform for cannabis.

Having built a relationship with Namaste as a client over the past two years, we found that we share many of the same core values, work ethic, and passion for building products that people love. We’re confident that the merging of our teams will enable us to continue innovating in this fast-paced, growing industry.”

Laurens Feenstra, Director of Namaste, an A.I. expert, and Product Manager for Google Waymo comments: “I am super excited for the talented team of Findify to join Namaste! Their leading machine learning models have already made Namaste much better at recommending the right products to our customers. And, even more importantly, we are thrilled to apply their deep A.I. expertise to cannabis. There are approximately 800 identified strains of cannabis each with hundreds of active ingredients, meaning each plant works differently for each person. Understanding which plant works for whom will be key in helping cannabis benefit everyone.”

Sean Dollinger, President and CEO of Namaste comments: “We’re very pleased to announce the acquisition of Findify. This is a very exciting opportunity for Namaste to forge new ground in the cannabis industry by introducing what we believe to be the most innovative technology for on-site personalization. Moving forward we believe global cannabis patients will demand a more customized online experience, as products and services in the cannabis industry continue to grow exponentially. Having worked with Findify as a client, we have witnessed excellent results through the implementation of their technology and believe strongly in the quality of their management team. Based on the success we have seen in the utilization of similar technology in other industries, we are extremely excited and optimistic to become the first company to introduce this incredible technology into the cannabis market and further enhance the online experience for cannabis patients.

Our vision for the Company in becoming a global leader in medical cannabis technology is evident from the addition of our new board members coming from Google and SpaceX, industry leaders in the areas of machine learning and A.I. that chose to join Namaste’s team. Furthermore, this acquisition represents a major milestone for Namaste in solidifying itself as one of the most innovative technology companies in the cannabis industry.”

About Findify AB

Findify is a leader in e-commerce machine learning applications, with over 1200 customers in more than 60 countries around the world. Findify has developed a unique machine learning core, that leverages user behaviour, to personalize online experiences in real-time. Findify’s machine learning technology has been proven to deliver up to 27% uplift in conversion rate, and up to 30% uplift in revenue per user.

Findify is an official Shopify Plus Technology Partner, recognized as a “Best-In-Class Solution” for modern, rapidly growing e-Commerce businesses.

About Namaste Technologies Inc.

Namaste Technologies is a global leader in the sale of medical cannabis consumption devices. Namaste has nine offices with multiple distribution centers around the globe and operates over 30 websites under various brands. Namaste has developed innovative technology platforms including NamasteMD.com, Canada’s first ACMPR compliant telemedicine application. The company is focused on patient acquisition through NamasteMD and intends on building Canada’s largest database of medical cannabis patients. The company’s subsidiary, CannMart Inc. is an ACMPR Licensed Producer with a “sales-only” license, whereby the company will offer a large variety of medical cannabis sourced from domestic and international producers. Namaste will continue to develop and acquire innovative technologies which will provide value to the Company and to its shareholders as well as to the broader cannabis market.

On behalf of the Board of Directors

“Sean Dollinger”
Chief Executive Officer
Direct: +1 (786) 389 9771
Email: [email protected]

Further information on Namaste and its products can be accessed through the links below:
namastetechnologies.com
namastevapes.ca
everyonedoesit.ca
namastevaporizers.co.uk
everyonedoesit.co.uk
australianvaporizers.com.au

Forward Looking Information

This press release contains forward-looking information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, Namaste assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents, which can be found under the Company’s profile on www.sedar.com. This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward looking statements are made pursuant to the safe harbour provisions of the Private Securities Litigation Reform Act of 1995. Neither the TSX Venture Exchange nor its market regulator has reviewed or approved the contents of this press release.

Tags: , , , , , , ,
Posted in All Recent Posts, Featured, Medical Marijuana Stocks, Namaste Technologies Inc. | Comments Off on Namaste $N.ca Acquires #Findify, a Leading A.I. and Machine Learning Company, to Increase Conversion Rates, Average Order Value, Retention and Referrals $ACB.ca $HIP.ca $WEED.ca $CMED.ca

Marijuana Company of America $MCOA and Global Hemp Group Announce Acquisition of 109 Acres of Prime Agricultural Property for Hemp CBD Production in Oregon $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 8:27 AM on Tuesday, May 1st, 2018

15233 mcoa

  • Company, in partnership with Global Hemp Group Inc.has acquired a 109-acre agricultural property in Scio, Oregon
  • For the cultivation of high CBD yielding hemp for the upcoming 2018 growing season

Escondido, California–(May 1, 2018) – MARIJUANA COMPANY OF AMERICA, INC. (OTC: MCOA) (“MCOA” or the “Company”) is pleased to announce that the Company, in partnership with Global Hemp Group Inc. (CSE: GHG) (OTC: GBHPF) (FSE: GHG) has acquired a 109-acre agricultural property in Scio, Oregon (the “Property”) for the cultivation of high CBD yielding hemp for the upcoming 2018 growing season.

This particular property was chosen as it has a history of hemp cultivation over the last two growing seasons and contains a high level of organic matter in the soil, which makes it ideal for hemp cultivation. In addition, the property has appropriate irrigation infrastructure that includes sufficient authorized water rights to allow for irrigated cultivation, which is expected to greatly enhance yields of the proposed high CBD hemp cultivars that the partners are planning to grow on the property.

The property, located in the fertile Willamette Valley approximately 70 miles south of Portland, Oregon, was acquired for US$1.1 million. The terms of the acquisition include a cash down payment of US$130,000 and the issuance of 2,100,000 common shares in the share capital of GHG valued at US$275,000, to be delivered within 15 days of closing. The partners are each contributing one half of the cash consideration for the down payment purposes, or the amount of US$65,000. MCOA is also contributing a cash payment equal to one-half of the value of GHG’s stock consideration, or the amount of US$137,500, that will be paid from the expected profits to be produced from the project during the first year of operations.

The GHG common shares to be issued pursuant to the Acquisition Agreement are considered to be issued on a private placement basis, according to the CSE Policy 6. Such common shares are subject to a customary one (1) year hold period pursuant to the provisions of Rule 144 of the Securities Act of 1933. The balance, the amount of US$695,000, is a promissory note (“the Note”) issued to the current owner, which matures on May 1, 2021. Interest on the Note is set at 4.0% per annum, adjustable on the first day of October each year, based on the closing interest rate of the Ten-Year U.S. Treasury Note on September 30th plus 1.15%. The Note calls for monthly payments of US$7,036.54 beginning as of June 1, 2018, and a final payment of the remaining balance on May 1, 2021.

The partners have been exploring hemp cultivation and cannabinoid extraction opportunities in the U.S. Pacific Northwest for more than a year. The State of Oregon was chosen for this project due to climate considerations, the current regulatory environment in the State and availability of local experienced personnel.

About Marijuana Company of America, Inc.
MCOA is a corporation which participates in: (1) product research and development of legal hemp-based consumer products under the brand name “hempSMART™”, that targets general health and well-being; (2) an affiliate marketing program to promote and sell its legal hemp-based consumer products containing CBD; (3) leasing of real property to separate business entities engaged in the growth and sale of cannabis in those states and jurisdictions where cannabis has been legalized and properly regulated for medicinal and recreations use; and, (4) the expansion of its business into ancillary areas of the legalized cannabis and hemp industry, as the legalized markets and opportunities in this segment mature and develop.

About Global Hemp Group Inc.
Global Hemp Group Inc. (CSE: GHG) (OTC: GBHPF) (FSE: GHG), headquartered in Vancouver, British Columbia, Canada, with base operations in Montreal and Los Angeles, is a publicly traded company founded in 2014. The Company is focused on a multi-phased strategy to build a strong presence in the industrial hemp industry in both Canada and the United States. The first phase of this strategy is to develop hemp cultivation with the objective of extracting cannabinoids (CBD, CBG, CBN & CBC) and creating a near term revenue stream that will allow the Company to expand and develop successive phases of the strategy. The second phase of the plan will focus on the development of value-added industrial products utilizing the processing of the whole hemp plant, as envisioned in the Company’s Hemp Agro-Industrial Zone (HAIZ) strategy.

Forward Looking Statements
This news release contains “forward-looking statements” which are not purely historical and may include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities and words such as “anticipate”, “seek”, intend”, “believe”, “estimate”, “expect”, “project”, “plan”, or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects, the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based products. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-12G, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission. For more information, please visit www.sec.gov.

For more information, please visit the Company’s websites at:

MarijuanaCompanyofAmerica.com
hempSMART.com
NetworkNewsWires/MCOA

 

Corporate Communications Contact:
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
[email protected]

Tags: , , , , ,
Posted in All Recent Posts, Marijuana Company of America, Medical Marijuana Stocks | Comments Off on Marijuana Company of America $MCOA and Global Hemp Group Announce Acquisition of 109 Acres of Prime Agricultural Property for Hemp CBD Production in Oregon $AERO $CBDS $CGRW $APH.ca $GBLX

Namaste $N.ca $NXTTF Announces Record-Breaking Quarterly Sales of $5.6M Representing a 195% Quarter-Over-Quarter Increase and Over 1,600 Medical Cannabis Patients $ACB.ca $HIP.ca $WEED.ca $CMED.ca

Posted by AGORACOM-JC at 10:09 AM on Monday, April 30th, 2018

Nlogo

  • Sales for the second quarter of 2018 were $5.6M,
    • representing a $3.7M or 195% increase quarter-over-quarter 
  • Gross profit for the second quarter of 2018 was $1.9M,
    • representing a $1.2M or 150% increase quarter-on-quarter
  • Over 1,600 Medical Cannabis Patients Acquired To-Date Through NamasteMD

VANCOUVER, British Columbia, April 30, 2018 — Namaste Technologies Inc. (“Namaste” or the “Company”) (CSE:N), (FRANKFURT:M5BQ), (OTCMKTS:NXTTF) is pleased to announce the filing of its unaudited quarterly financial statements, management’s discussion and analysis and certification of the quarterly filings for the second quarter of fiscal 2018. The statements for the period can be accessed on the Company’s SEDAR profile at www.sedar.com.

The Company’s sales for the second quarter of 2018 were $5.6M, representing a $3.7M or 195% increase quarter-over-quarter.  Gross profit for the second quarter of 2018 was $1.9M, representing a $1.2M or 150% increase quarter-on-quarter. For the first six months of the year, the Company had sales of $10.6M, representing a $6.6M or 165% increase year-on-year. Gross profit for the first six months of 2018 was $3.6M, representing a $2.1M or 140% increase year-over-year. The gross profit increase relates primarily to the growth in revenue outside the United States.

Namaste’s management team is extremely encouraged by the financial position of the Company and anticipates seeing accelerated growth in Q3 and Q4 of 2018. The Company has been focused on launching many new initiatives, the most significant of which is the addition of medical cannabis sales through the Company’s wholly-owned subsidiary, Cannmart Inc. (“Cannmart”). Namaste will focus on expanding its international platform and in developing new opportunities domestically and abroad.

The Company has also seen a significant impact on Canadian operating costs for its hardware business, correlated to the integration of Namaste’s platform with Greenlane Canada Inc., whereby inventory management and order processing are fulfilled by Greenlane. The integration with Greenlane has completely removed all inventory costs and has also streamlined operations. The Company anticipates further cost reductions by pursuing similar strategic partnerships which bring long-term value to the Company and its shareholders.

Namaste’s management team is now highly focused on patient acquisition through the Company’s innovative telemedicine application, NamasteMD. To date, the company has acquired over 1,600 patients, all of which were driven organically through Namaste’s platform. The Company’s marketing team will be working through various marketing channels to further accelerate patient growth while expanding its clinic team in order to accommodate anticipated demand. With strong initial results on patient acquisition costs and conversion rates, Namaste believes that it will be able to acquire medical patients faster and at a lower cost than any of its industry peers.

The Company is also looking forward to trading on the TSX Venture Exchange (“TSXV”) as a Tier 1 issuer, which will provide Namaste and its shareholders with many advantages, including greater visibility and enhanced market access for Canadian and international investors.

Quarterly Financial Highlights

  • The majority of revenues were generated by several key markets. The top five countries generated 85% of revenues for the second quarter of 2018 compared to 84% for the second quarter of 2017. The table below depicts gross revenues by country.
Revenues by country
For three months ended For six months ended
Country February 28,
2018		 February 28,
2017		 February 28,
2018		 February 28,
2017
United Kingdom $1,346,193.00 $737,946.00 $2,580,175.81 $1,285,227.00
Australia $1,234,429.00 $91,371.00 $2,650,200.00 $170,254.62
United States of America $1,140,217.00 $525,518.00 $1,817,768.84 $1,437,529.00
Brazil $380,879.00 $100,591.00 $735,322.92 $202,514.00
Canada $678,815.00 $78,985.00 $1,034,446.63 $159,223.00
Germany $287,878.00 $32,660.00 $550,487.86 $56,097.00
New Zealand $71,714.00 $75,149.00 $176,197.59 $209,317.00
Ireland $36,902.00 $51,759.00 $98,722.14 $87,264.00
Israel $94,160.00 $26,367.00 $157,004.13 $48,603.00
Other $362,643.00 $186,760.00 $764,614.08 $338,265.38
Total $5,633,830.00 $1,907,106.00 $10,564,940.00 $3,994,294.00
  • Operating costs for the second quarter of 2018 were $5.5M compared to $2.4M for the second quarter of 2017. The $3.1M quarter-over-quarter increase in operating costs is primarily due to non-cash charges of $1.5M, which included share-based compensation, amortization of intangible assets, and depreciation.
  • Selling expenses for the second quarter of 2018 were $1.7M compared to $0.6M for the second quarter of 2017, representing an increase of $1.1M quarter-on-quarter. The increase was due in part to an increase in advertising expenses of $0.6M and consulting expenses of $0.5M. Advertising expenses related to online search services as well as other online promotional and social media tools utilized by the Company to generate sales. These costs further represent the Company’s significant investment into search engine optimization and its ongoing customer acquisition strategy. Consulting expenses relate to compensation amounts paid to various companies and individuals for marketing, order fulfillment, customer service activities, e-commerce product development, back-office e-commerce support and sales commissions. The increase in consulting fees is primarily related to information technology in order to develop current and new revenue channels.
  • Administration expenses for the second quarter of 2018 were $3.5M compared to $1.8M for the second quarter of 2017, representing an increase of $1.7M quarter-over-quarter. The increase is primarily due to share-based compensation of $1.3M and increases in merchant fees and professional fees.
  • Other expenses for the second quarter of 2018 were $0.3M compared to approximately $nil for the second quarter of 2017, representing an increase of $0.3M quarter-over-quarter. The increase was primarily due to the amortization of intangibles of $0.2M, which relates to the amortization of the customer list from the acquisition of Australian Vaporizers.

Management Commentary
Sean Dollinger, President and CEO of Namaste comments: “We are very pleased with the Q2 financials. The Company continues to see quarter-on-quarter growth at a rapidly accelerating rate, even after having divested our US assets. Our management team remains focused on ramping up patient acquisition through NamasteMD, and we anticipate launching medical cannabis sales through Cannmart in the near future. Namaste will continue to pursue and develop innovative technologies for the cannabis industry. This will be achieved through forming mutually beneficial partnerships and in making strategic investments that bring value to both the Company and the cannabis sector as a whole. We feel that the Company is now positioned for significant growth going forward which will be achieved by accelerating patient acquisition, adding medical cannabis sales to our platform and by implementing new technologies to an already impressive platform.”

About Namaste Technologies Inc.
Namaste is the largest online retailer for medical cannabis delivery systems globally. Namaste distributes vaporizers and smoking accessories through e-commerce sites in 24 countries and with 5 distribution hubs located around the world. Namaste has majority market share in Europe and Australia, with operations in the UK, Canada and Germany and has opened new supply channels into emerging markets including Brazil, Mexico and Chile. Namaste, through its acquisition of Cannmart Inc., which operates a medical cannabis “sales-only” license under Canada’s Access to Cannabis for Medical Purposes Regulations (“ACMPR”), is pursuing a new revenue vertical in online retail of medical cannabis in the Canadian market. Namaste intends to leverage its existing database of Canadian medical cannabis consumers, along with its expertise in e-commerce to create an online marketplace for medical cannabis patients, offering a larger variety of product and a better user experience.

Forward Looking Information
This press release contains forward-looking information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions. The Company assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com.

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The CSE has neither reviewed nor approved the contents of this press release.

On behalf of the Board of Directors
“Sean Dollinger”
Chief Executive Officer Direct: +1 (786) 389 9771
Email: [email protected]

Further information on Namaste and its products can be accessed through the links below:

www.namastetechnologies.com
www.namastevaporizers.co.uk
www.everyonedoesit.co.uk
www.australianvaporizers.com.au

Tags: , , ,
Posted in All Recent Posts, Featured, Medical Marijuana Stocks, Namaste Technologies Inc. | Comments Off on Namaste $N.ca $NXTTF Announces Record-Breaking Quarterly Sales of $5.6M Representing a 195% Quarter-Over-Quarter Increase and Over 1,600 Medical Cannabis Patients $ACB.ca $HIP.ca $WEED.ca $CMED.ca

Tetra Bio-Pharma $TBP.ca Signs Landmark Commercialization Term Sheet for its Lead Pharmaceutical Product, PPP001, in Israel #MMJ #Marijuana $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 9:14 AM on Tuesday, April 24th, 2018

Logo tetrabiopharma rgb web

  • Company has signed a first binding term sheet for the marketing and distribution of PPP001 in Israel with Kamada Ltd
  • Signing of a Definitive Distribution Agreement is expected to follow shortly
  • PPP001 is being developed to be the first smokable cannabis product for advanced cancer pain available under prescription

OTTAWA, ONTARIO–(April 24, 2018) – Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX VENTURE:TBP) (OTCQB:TBPMF), announced today that the Company has signed a first binding term sheet for the marketing and distribution of PPP001 in Israel with Kamada Ltd., a leading pharmaceutical company. The signing of a Definitive Distribution Agreement is expected to follow shortly. PPP001 is being developed to be the first smokable cannabis product for advanced cancer pain available under prescription.

This first international market commercialization agreement represents a significant milestone and a validation of Tetra Bio-Pharma’s business model with a leading Israel-based pharmaceutical company. Israel, like Canada, is considered one of the world leaders in the production and development of cannabinoid-based products. Kamada is a company with two FDA-approved products and an Israeli-based distribution segment that has demonstrated continued growth. Tetra Bio-Pharma intends to work closely with Kamada as PPP001 advances towards regulatory approval and commercial launch in Israel.

Under the terms of the anticipated final agreement, Kamada will be responsible for registering the product, as well as all marketing and distribution, in Israel. Tetra will be eligible to receive certain milestone payments and an undisclosed percentage of the sales of PPP001 generated by Kamada in Israel.

About PPP001 

On April 4, 2018, Tetra Bio-Pharma officially started the Phase 3 trial for PPP001 indicated for terminal stage cancer patients with a goal to improving the quality of life of these patients as well as minimizing their pain. PPP001 is being developed to be the first smokable cannabis product for advanced cancer pain available under prescription.

About Tetra Bio-Pharma: Tetra Bio-Pharma (TSX VENTURE:TBP) (OTCQB:TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and clinical development. Tetra is focusing on three core business pillars: clinical research, pharmaceutical promotion and retail commercialization of cannabinoid-based products. Tetra Bio-Pharma is currently developing a pipeline of five cannabinoid-based products using different delivery systems such as smokable pellets, oral tablets, eye drops and topical ointments. More information at: www.tetrabiopharma.com

Source: Tetra Bio-Pharma

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a license for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Tetra Bio-Pharma Inc.
Robert (Bob) Béchard
Vice President Finance and Business Development
[email protected]
M: +1 514 817-2514

For media information, please contact:
Daniel Granger
[email protected]
ACJ Communication
O: +1 514 840 7990
M: +1 514 232 1556

Tags: , , , ,
Posted in All Recent Posts, Medical Marijuana Stocks, Tetra Bio-Pharma Inc. | Comments Off on Tetra Bio-Pharma $TBP.ca Signs Landmark Commercialization Term Sheet for its Lead Pharmaceutical Product, PPP001, in Israel #MMJ #Marijuana $AERO $CBDS $CGRW $APH.ca $GBLX

The medical #marijuana industry is about to get much bigger, CannTrust CEO says $N.ca $NXTTF $TBP.ca $MCOA $ACB.ca $HIP.ca $WEED.ca $CMED.ca

Posted by AGORACOM-JC at 12:11 PM on Friday, April 20th, 2018
  • The ramp up in Canada’s cannabis sector is ongoing
  • Industry estimates of sales eventually adding up to between $5 and $8 billion a year
  • By comparison, Canada produces a little under $3 billion of beer a year and about $1 billion in tobacco products.

April 19, 2018 By Jayson MacLean

Eric Paul

While all eyes are on the launch date for recreational cannabis in Canada —said to come in either late summer or early fall— the medical side of the equation should be getting the attention, as well, because it’s about to get much bigger, says Eric Paul, CEO of licensed producer CannTrust Holdings (TSX:TRST).

The ramp up in Canada’s cannabis sector is ongoing, with industry estimates of sales eventually adding up to between $5 and $8 billion a year. That’s substantial, since by comparison, Canada produces a little under $3 billion of beer a year and about $1 billion in tobacco products.

But while the rec market is getting all the focus, the medical marijuana industry both at home and abroad should be getting its props, since it’s growing by leaps and bounds.

“We’ve been astounded by the growth of the medical marijuana industry in Canada,” Eric Paul, CEO of CannTrust Holdings, tells BNN.

“Roughly ten or 12 per cent of the 80,000 doctors across Canada who could prescribe are prescribing [cannabis], and I would say we’re gaining on that for a number of reasons,” says Paul. “The first being the opiate crisis where doctors are looking for cannabis as a potential first-line therapy for pain management. The second thing is that there is more research coming out; we’re about to announce a couple of major research projects in Canada and one is a major pain management study. As these research projects produce their end result, more doctors are looking at cannabis as an alternate therapy for chronically ill people.”

Statistics Canada has reported that between April and December of last year, the number of clients registered under its Access to Cannabis for Medical Purposes Regulations (ACMPR) has gone from 174,503 to 269,502.

Paul says that CannTrust itself has a 40,000-strong patient base and is looking to jump to 100,000 in 12 months time.

“We’ve had a major expansion in Niagara: a 430,000 sq. ft. state of the art greenhouse which is up and running,” says Paul. “We believe that with that capacity and with the nature of that facility, we’ll be able to supply our current customer demand in the medical market and have sufficient capacity to handle the first generation of recreational demand.”

But aside from Canada’s own growing medical market, the international market is poised to take off in countries like Germany and Australia, and many of the top licensed producers in Canada are now lining up deals outside of Canada.

In March, CannTrust announced that it has entered into a joint venture agreement with a Danish company to grow and sell medical cannabis.

“The industry is globalizing much faster than any of us expected,” says Paul.

“Various countries are going into medical legislation and Denmark is one of those countries that have announced that we’re fully licensed there, we’ll be building a facility there,” he said. “In that country, the government has decided to fund the cost of it for the consumer, via prescription, and they’re willing to fund 100 per cent for people with palliative or end-of-life care and 50 per cent for chronic illness. That will allow those industries to quickly garner market share. Germany is a similar kind of situation and also Australia.”

Source: https://www.cantechletter.com/2018/04/the-medical-marijuana-industry-is-about-to-get-much-bigger-canntrust-ceo-says/

Tags: , , , , , ,
Posted in All Recent Posts, Marijuana Company of America, Medical Marijuana Stocks, Namaste Technologies Inc., Tetra Bio-Pharma Inc. | Comments Off on The medical #marijuana industry is about to get much bigger, CannTrust CEO says $N.ca $NXTTF $TBP.ca $MCOA $ACB.ca $HIP.ca $WEED.ca $CMED.ca

Medical #marijuana making a big difference in the lives of sick children and their families $TBP.ca $N.ca $NXTTF $MCOA $ACB.ca $HIP.ca $WEED.ca $CMED.ca

Posted by AGORACOM-JC at 11:06 AM on Wednesday, April 11th, 2018

“That makes all of the work we did worthwhile.”

ByCharlie Deitch @CharlieDee71

CP photo by Renee Rosensteel, Hannah Pallas laughs with her mother, Heather Shuker

Stretched out in his recliner, Ryan Briggs is having a great nap. Laying there in his Bob Marley T-shirt, you can hear him gently snoring. Although his slumber is intermittently interrupted by a slight seizure, this is starting out as a good day.

At just 18, Briggs has already had a pretty rough life. When he was born, doctor error caused the child to go more than 20 minutes without oxygen. Briggs lived, but is nonverbal and unable to care for himself. Worse than that, though, were the seizures. He experienced close to 500 of them every day — some smaller, others larger and more violent. He received all kinds of treatments and medication, but few of them helped; some made things even worse. But his mother, Diana Briggs, was determined to keep looking for that one thing that would help.

“We went everywhere for treatment,” she says. “We did one called the starvation diet, we did hyperbaric treatments and even went out of the country for stem-cell treatments. But nothing seemed to help. The seizures would get so bad, and they were frequent. We tracked every one of them. In fact, that’s how my youngest daughter learned to count, by counting her brother’s seizures.”

In 2014, Briggs saw a video that changed her life. It provided the same epiphany that parents across the state would have as the video was shared widely. The video showed that oil extracted from marijuana worked to stop the seizures of a 5-year-old Colorado girl named Charlotte Figi. Subsequently, a large group of parents across the state banded together to fight to bring medical marijuana to Pennsylvania. It was an uphill fight, but on April 17, 2016, Gov. Tom Wolf signed the legislation into law, and earlier this year, Pennsylvanians could begin legally purchasing medical cannabis.

There is no question that without the parents of sick children stepping forward to fight this battle, the law would never have been approved. But, as Briggs says, “It’s easy to say no to an adult, but it’s pretty hard to do that to a sick kid who’s suffering.”

click to enlarge

  • Ryan Briggs and his family pose for a photo with Gov. Tom Wolf the day he signed the medical-marijuana bill into law.

When the World Medical Cannabis Conference & Expo opens in Pittsburgh later this week, there will be many panels on “children and cannabis.” With that in mind, City Paper checked in on some families who have spent the past four years fighting for legalization and see how their lives have changed. Aside from Briggs, we also talked to Heather Shuker, an outspoken advocate for the product and the mother of Hannah Pallas, a 15-year-old who has dealt with intractable epilepsy her entire life.

“A few years ago, Hannah was confined to a chair, she never smiled, she couldn’t lift her extremities, she was non-verbal,” Shuker says, as a walking, squealing Hannah moves about their apartment from room to room. “Look at her now. She has found her voice, and she has found her smile again. It’s an amazing transformation.”

An obvious positive of medical-marijuana dispensaries opening up across the state is having available product close by. But for many parents, this won’t be the first time they’ve purchased these medications. Last year, the state enacted a safe-harbor provision that made it legal for anyone who is qualified to receive the drug to have it in their possession. Many parents began going out of state for the product, and since it was still illegal in several states, transporting it over state lines was a felony. For other parents, though, having safe-harbor protections still wasn’t their first foray into buying medical marijuana.

“I haven’t talked about this much before, obviously, but we’ve been experimenting with Hannah’s medication for a few years now,” Shuker says. Sometime between 2014 and 2015, Shuker began going out of state to get medical-marijuana products. She always traveled by plane and brought the oils back with her on the plane, a nerve-wracking experience. “I knew it was a risk, and I knew it would be bad if I got caught, because someone could try to take Hannah away,” she says. “But my daughter was sick, with zero quality of life. I had to help her, so at the end of the day, it wasn’t really a choice at all.”

Briggs had the same feeling that Shuker did. She would fly to Colorado to get medication and bring it back with her. Once, because of some change she forgot to take out of her pocket, she was pulled aside and given a complete search, including having her bags searched. They didn’t find the oil, but it made for a tense moment.

Because of the cost of going to Denver and the risk, she decided to find a local contact. While she won’t give many details about the person or the transactions, she says the dealer became part of the family.

“That first Christmas, I baked him some cookies,” Briggs says. “I didn’t think it was strange at the time. I’m a mom — that’s what we do for family and friends, we bake cookies.”

The other thing moms do is help others in need.

Source: https://www.pghcitypaper.com/pittsburgh/medical-marijuana-making-a-big-difference-in-the-lives-of-sick-children-and-their-families/Content?oid=7667617

Tags: , ,
Posted in All Recent Posts, Marijuana Company of America, Medical Marijuana Stocks, Namaste Technologies Inc., Tetra Bio-Pharma Inc. | Comments Off on Medical #marijuana making a big difference in the lives of sick children and their families $TBP.ca $N.ca $NXTTF $MCOA $ACB.ca $HIP.ca $WEED.ca $CMED.ca

Namaste $N.ca Announces March 2018 Sales of C$1.24M Representing a 74% Year-on-Year Increase and Acquires 535 New Patients Representing a 142% Month-on-Month Increase $ACB.ca $HIP.ca $WEED.ca $CMED.ca

Posted by AGORACOM-JC at 9:26 AM on Friday, April 6th, 2018

Nlogo

  • March net revenue C$1,249,670
    • 74% revenue increase in March 2018 when compared to March 2017
  • Namaste MD acquired 535 new medical cannabis patients on the NamasteMD platform
    • 142% month-over-month increase of patients
    • Company anticipates further acceleration of the growth
    • will be key driver of future revenue

VANCOUVER, British Columbia, April 06, 2018 —Namaste Technologies Inc. (“Namaste” or the “Company”) (CSE:N) (FRA:M5BQ) (OTCMKTS:NXTTF) is pleased to announce March 2018 total unaudited net revenue as reported by the Company (including shipping revenues and after discounts and refunds) were C$1,249,670, representing a 74% revenue increase in March 2018 when compared to March 2017. Namaste’s management team is also pleased to report that the Company’s wholly owned subsidiary, Namaste MD Inc. (“NamasteMD”), has acquired 535 new medical cannabis patients on the NamasteMD platform, representing a 142% month-over-month increase of patients. NamasteMD allows patients to consult with doctors or nurse practitioners for medical cannabis in a simple and convenient platform from the comfort of their homes. The Company anticipates further acceleration of the growth in the NamasteMD patient network and expects that NamasteMD will be key driver of future revenue.

The table below display’s Namaste’s total gross sales by revenue channel.

Management Commentary

Sean Dollinger, President and CEO of Namaste comments; “We are very pleased to be seeing the positive trend of monthly sales increases year-over-year. What is most exciting is our increasing rate of patient acquisition on NamasteMD. With minimal outside marketing we were quietly able to bring on nearly 1,000 patients by the end of the March. We are working on expanding our nurse practitioner team with our partners at O Cannabis we Stand on Guard for Thee Inc. (“O Cannabis”) to accommodate the anticipated growth of patients. We strongly believe that our patients will be a key to our success, along with our strategy to provide our patients with not only the best care but also the largest and best variety of medical cannabis products. We’re proud to be innovating the industry by changing the way that patients access medical cannabis and look forward to continued growth through both the medical cannabis and hardware platforms.”

About Namaste Technologies Inc.

Namaste is the largest online retailer for medical cannabis delivery systems globally. Namaste distributes vaporizers and smoking accessories through 24 e-commerce sites in 20 countries and with distribution hubs located around the world. Namaste has majority market share in Europe and Australia, with operations in the UK, Canada and Germany and has opened new supply channels into emerging markets including Brazil, Mexico and Chile. Namaste, through its acquisition of Cannmart Inc., a Canadian based late-stage applicant for a medical cannabis sales licence (under the ACMPR Program) is pursuing a new revenue vertical in online retail of medical cannabis in the Canadian market. Namaste intends to leverage its existing database of Canadian medical cannabis consumers, along with its expertise in e-commerce to create an online marketplace for medical cannabis patients, offering a larger variety of product and a better user experience.

On behalf of the Board of Directors

“Sean Dollinger”

Chief Executive Officer

Direct: +1 (786) 389 9771

Email: [email protected]

 

Further information on Namaste and its products can be accessed through the links below:

namastetechnologies.com

namastevapes.ca

everyonedoesit.ca

namastevaporizers.co.uk

everyonedoesit.co.uk

australianvaporizers.com.au

Forward Looking Information

This press release contains forward-looking information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, Namaste assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents, which can be found under the Company’s profile on www.sedar.com. This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward looking statements are made pursuant to the safe harbour provisions of the Private Securities Litigation Reform Act of 1995. The Canadian Securities Exchange has neither reviewed nor approved the contents of this press release.

Tags: , , , , ,
Posted in All Recent Posts, Featured, Medical Marijuana Stocks, Namaste Technologies Inc. | Comments Off on Namaste $N.ca Announces March 2018 Sales of C$1.24M Representing a 74% Year-on-Year Increase and Acquires 535 New Patients Representing a 142% Month-on-Month Increase $ACB.ca $HIP.ca $WEED.ca $CMED.ca

Namaste $N.ca Announces Canada’s First Large-Scale National Prospective Observational Study to Observe the Impact of Medical #Cannabis Use for Anxiety Treatment $ACB.ca $HIP.ca $WEED.ca $CMED.ca

Posted by AGORACOM-JC at 9:51 AM on Wednesday, April 4th, 2018

Nlogo

  • Initiated Canada’s first large-scale prospective study on a national platform called the Cannabis for Anxiety Reduction study, to determine the effectiveness of cannabis in reducing anxiety in study participants
  • One in four Canadians suffer from anxiety and the Company through this study will seek to gain valuable information from study participants on the impact of medical cannabis use in relation to their anxiety

VANCOUVER, British Columbia, April 04, 2018 – Namaste Technologies Inc. (“Namaste” or the “Company”) (CSE:N) (FRANKFURT: M5BQ) (OTCMKTS:NXTTF) is pleased to announce that it has initiated Canada’s first large-scale prospective study on a national platform called the Cannabis for Anxiety Reduction study, to determine the effectiveness of cannabis in reducing anxiety in study participants. One in four Canadians suffer from anxiety and the Company through this study will seek to gain valuable information from study participants on the impact of medical cannabis use in relation to their anxiety. Namaste is also interested in determining the safety profile of patients using medical cannabis, and whether strain and dose of medical cannabis may impact patient reductions in anxiety ratings. The study will be available to all Canadians and will be conducted under the following conditions:

  • Prospective patients must be over 25 years of age.
  • Patients must score 8 or above Hospital Anxiety and Depression Scale (HADS).
  • The study will span over a 3-month period for each registered patient.
  • The study will be submitted for approval to the Veritas Independent Review Board (IRB) prior to commencement.
  • The primary investigator in the study is a nurse practitioner.
  • Patients can self-refer into the study (without referral through a doctor or specialist).

Namaste plans to offer this study to its patients which are registered under the Company’s wholly-owned subsidiary and virtual patient platform, NamasteMD Inc. (“NamasteMD”). Patients suffering from anxiety under the terms outlined above may participate in the study. This study is the first large-scale anxiety study in the nation, establishing Namaste as an innovator in research related to anxiety and cannabis. This is also the first national study where the primary investigator is a nurse practitioner. The Company intends to conduct similar studies in various areas where patients can benefit from the use of medical cannabis. The data collected from the study is valuable for the Company as well as the industry as a whole. The study may be published in peer-reviewed research journals and other medical publications.

For more information on this study please email [email protected]

Management Commentary

Sean Dollinger, President and CEO of Namaste comments; “We are very pleased to have initiated this study with the help of our partners at O-Cannabis. As many people in Canada suffer from varying forms of anxiety, we believe that many of these patients can benefit from the use of medical cannabis instead of prescription pharmaceutical drugs. We hope this study will provide very valuable information for Namaste and for the industry. We encourage qualifying patients to participate and look forward to seeing the results. We plan to undertake additional studies to bring awareness and a better understanding of how medical cannabis can benefit Canadians. We believe that these studies will help Namaste by attracting a larger base of patients and help solidify Namaste’s position as a leader in the Canadian medical cannabis industry.”

About Namaste Technologies Inc.

Namaste is the largest online retailer for medical cannabis delivery systems globally. Namaste distributes vaporizers and smoking accessories through 24 e-commerce sites in 20 countries and with distribution hubs located around the world. Namaste has majority market share in Europe and Australia, with operations in the UK, Canada and Germany and has opened new supply channels into emerging markets including Brazil, Mexico and Chile. Namaste, through its acquisition of Cannmart Inc., is pursuing a new revenue vertical in online retail of medical cannabis in the Canadian market. Namaste intends to leverage its existing database of Canadian cannabis consumers, along with its expertise in e-commerce to create an online marketplace for medical cannabis patients, offering a larger variety of product and a better user experience.

On behalf of the Board of Directors

“Sean Dollinger”
Chief Executive Officer
Direct: +1 (786) 389 9771
Email: [email protected]

Further information on the Company and its products can be accessed through the links below:

NamasteTechnologies.com
NamasteMD.com
NamasteVapes.ca
Everyonedoesit.ca

FORWARD LOOKING INFORMATION This press release contains forward-looking information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, Namaste assumes no responsibility to update or revise forward looking information to reflect new events or circumstances unless required by law. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com. This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The CSE has neither reviewed nor approved the contents of this press release.

 

Tags: , , , ,
Posted in All Recent Posts, Medical Marijuana Stocks, Namaste Technologies Inc. | Comments Off on Namaste $N.ca Announces Canada’s First Large-Scale National Prospective Observational Study to Observe the Impact of Medical #Cannabis Use for Anxiety Treatment $ACB.ca $HIP.ca $WEED.ca $CMED.ca

« Older Entries
Newer Entries »